Top View
- (12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
- (INN) for Biological and Biotechnological Substances
- Systemic Rheumatic Diseases from Biological Agents to Small Molecules
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Vol. 5 Issue 3: Member News
- The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19- Related Systemic Inflammatory Response
- Study Protocol and Amendments As Applicable
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- Izana Bioscience's Drug Namilumab Announced in Major UK COVID-19
- Treatment of Rheumatoid Arthritis with Biological Agents —As a Typical and Common Immune-Mediated Inflammatory Disease
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
- Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
- Gm, Ke, Lr, Ls, Mw, Mz, Na, Rw, Sd, Sl, St, Sz, Tz, Ug, Zm, Zw
- GM-CSF Targeted Immunomodulation Affects Host Response to M
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (INN) for Biological and Biotechnological Substances
- WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
- Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
- Phase 1B Randomized, Double-Blind Study of Namilumab, an Anti
- Antibodies[Version 1; Peer Review: 2 Approved]
- Spotlight on Mavrilimumab for the Treatment of Rheumatoid Arthritis: Evidence to Date
- CATALYST - an Early Phase Platform Trial in (Suspected) COVID-19
- Namilumab Or Infliximab Compared to Standard of Care in Hospitalised Patients with COVID-19 (CATALYST): a Phase 2 Randomised Adaptive Trial